Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience

doi:10.2147/CMAR.S259921

HFCAS OpenIR

	Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience
	Liu, Tongxin 1,2,3,4; Sun, Quanquan 1,2,3; Qin, Weifeng 1,2,3,4; Chen, Xiaozhong 1,2,3,4; Hu, Qiaoying 1,2,3,4
	2020
发表期刊	CANCER MANAGEMENT AND RESEARCH
ISSN	1179-1322
通讯作者	Hu, Qiaoying(huqy316@hotmail.com)
摘要	Purpose: Esthesioneuroblastoma (ENB) is a type of rare malignant neoplasm of the sinonasal cavity. Optimal treatment for ENB is still controversial. A retrospective study was conducted to identify the clinical outcome and optimal treatment for ENB in the era of intensity-modulated radiation therapy (IMRT). Patients and Methods: Between December 2006 and August 2018, 37 patients with ENB without distant metastasis who underwent neoadjuvant chemotherapy followed by chemoradiotherapy (C+RC) or surgery followed by radiotherapy or chemoradiotherapy (S+R/RC) were retrospectively reviewed at our center. Results: The median follow-up period was 63.7 months (range, 13.2-111.5 months). Five-year overall survival (OS), progression-free survival (PFS), locoregional relapse-free survival (LRFS), and distant metastasis-free survival (DMFS) were similar between treatment arms (P values > 0.05). With a multivariate analysis, a Karnofsky Performance Status (KPS) of <= 80 was a prognostic factor for poor five-year OS. A KPS of <= 80 and Kadish class C-D tumors were prognostic factors for poor PFS. A KPS of <= 80 was a prognostic factor for poor LRFS. When KPS was <= 80 and tumors were Kadish class C-D, T3-4 and Ni were prognostic factors for poor DMFS. Subgroup analyses also demonstrated that the two treatment arms exhibited similar trends for OS, PFS, LRFS, and DMFS, excluding patients with Ni or Kadish class A-B tumors (P values > 0.05). Conclusion: In the era of IMRT, S+R/RC failed to improve the outcomes of patients with ENB. C+RC may be a feasible treatment option for patients with ENB.
关键词	olfactory neuroblastoma neoadjuvant chemotherapy precise radiotherapy
DOI	10.2147/CMAR.S259921
关键词[WOS]	OLFACTORY NEUROBLASTOMA ; ADJUVANT CHEMOTHERAPY ; RESECTION ; CARCINOMA ; UTILITY
收录类别	SCI
语种	英语
资助项目	National Natural Science Foundation of China[81502647] ; National Natural Science Foundation of China[81502646] ; Zhejiang Medical and Health Science and Technology Project[2016KYB042] ; Zhejiang Medical and Health Science and Technology Project[2018KY298]
项目资助者	National Natural Science Foundation of China ; Zhejiang Medical and Health Science and Technology Project
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000571902200001
出版者	DOVE MEDICAL PRESS LTD
引用统计	被引频次：2[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/104261
专题	中国科学院合肥物质科学研究院
通讯作者	Hu, Qiaoying
作者单位	1.Univ Chinese Acad Sci, Dept Radiat Oncol, Canc Hosp, Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 2.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou 310022, Zhejiang, Peoples R China 3.Key Lab Radiat Oncol Zhejiang Prov, Hangzhou 310022, Zhejiang, Peoples R China 4.Key Lab Head & Neck Canc Translat Res Zhejiang Pr, Hangzhou 310022, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Liu, Tongxin,Sun, Quanquan,Qin, Weifeng,et al. Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience[J]. CANCER MANAGEMENT AND RESEARCH,2020,12.
APA	Liu, Tongxin,Sun, Quanquan,Qin, Weifeng,Chen, Xiaozhong,&Hu, Qiaoying.(2020).Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience.CANCER MANAGEMENT AND RESEARCH,12.
MLA	Liu, Tongxin,et al."Outcome and Optimal Treatment for Esthesioneuroblastoma in the Era of Intensity-Modulated Radiation Therapy: A Single-Center Experience".CANCER MANAGEMENT AND RESEARCH 12(2020).